UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

3B Pharmaceuticals

Radiopharmaceutical developer for cancer diagnostics and therapy

3B Pharmaceuticals logo

3B Pharmaceuticals

BiotechnologyBerlin, Germany

Radiopharmaceutical developer for cancer diagnostics and therapy

Visit WebsiteContact Company

About 3B Pharmaceuticals

Targeting cancer at the molecular level through nuclear medicine, 3B Pharmaceuticals GmbH is a privately held pharmaceutical R&D company headquartered in Berlin, Germany. The company's work sits at the intersection of imaging, therapy, and theragnostics, disciplines that together define the emerging field of targeted radiotherapy.

The company maintains an active pipeline of radiopharmaceutical assets, referred to internally as 3BP Assets, with programmes progressing through clinical trials. Its technology platform spans the development and application of radiopharmaceuticals and isotopes, providing the scientific foundation for both diagnostic imaging and therapeutic interventions. This dual imaging-and-therapy capability, known as theragnostics, positions the company within one of the more technically demanding areas of modern oncology drug development.

Partnering is an explicit part of the company's model, and 3B Pharmaceuticals engages with external collaborators to advance its pipeline. Its published research contributes to the broader scientific literature on nuclear medicine, reflecting the R&D intensity of its operations. The company operates from its Berlin facility and is reachable through a named contact and directions infrastructure on its site, indicating an active, functioning organisation.

For industry professionals, investors, or prospective partners working in nuclear medicine or radiopharmaceutical development, 3B Pharmaceuticals represents a focused, specialist player in a sector attracting considerable strategic interest across the global pharmaceutical industry.

Further information is available at 3b-pharma.com.

Areas of Expertise

Clinical TrialsOncology ImagingRadiopharmaceuticals

Services & Capabilities

Clinical TrialsOncology ImagingRadiopharmaceuticals
Similar Companies

More in Biotechnology

A

Alchemab Therapeutics

A proprietary platform for mining human antibody repertoires sits at the core of Alchemab Therapeutics, a clinical-stage biotechnology company working to identify novel drug targets and therapeutics by reverse engineering the biology of resilient patients. Rather than starting from disease biology alone, the approach begins with well-defined patient samples drawn from individuals who are susceptible to a condition yet remain protected from it, using deep B cell sequencing and computational analysis to identify convergent protective antibody responses across that population. The platform is designed to surface drug candidates that conventional discovery programmes are unlikely to find, making it particularly well suited to hard-to-treat diseases where existing therapeutic options remain limited. Alchemab has built its initial pipeline around neurodegenerative conditions and oncology, two areas where unmet medical need remains high and mechanistic understanding of protective immunity is still emerging. Access to the highly specialised patient samples that power the platform depends on a network of partnerships with patient representative groups, biobanks, industry partners, and academic institutions. These collaborations are central to the company's discovery model, ensuring that the antibody repertoire data feeding the computational analysis pipeline reflects genuine protective biological signals rather than population averages. Alchemab is led by Chief Executive Officer Jane Osbourn, OBE, FMedSci, PhD, who brings substantial scientific and commercial experience from the biotech and pharmaceutical sector. The broader executive and scientific leadership team is described as combining deep domain expertise with an ambitious development agenda across the company's growing pipeline. Further information is available at alchemab.com.

View profile
A

Alacris Theranostics

Alacris Theranostics positions itself as a systems medicine company, delivering integrated next-generation sequencing (NGS) services and bioinformatics solutions designed to translate multi-modal omics data into actionable insights for researchers, pharmaceutical partners and healthcare professionals. Based in Germany, the company's core offering spans the full omics workflow, from NGS data generation through to computational interpretation. Its bioinformatics capability is presented as central to the value proposition, enabling clients to move from raw sequencing output to clinically and scientifically meaningful results without switching vendors or platforms. The company also offers immune repertoire analysis alongside its broader genomics portfolio. A distinctive element of Alacris Theranostics' research and development work is the ModCell digital twin concept, a computational modelling approach aimed at supporting personalised medicine applications. The Alacris-CMTA platform is referenced within this context, reflecting an ambition to connect molecular profiling with precision oncology decision-making. The company's stated mission is to make comprehensive NGS services accessible across the research and pharma sectors, with a declared focus on advancing precision medicine and improving patient outcomes. Its approach emphasises customisation, on the basis that each project and each patient presents distinct challenges that standardised pipelines may not adequately address. Quality management, equality and diversity commitments, and an environmental policy statement are all cited on its public-facing communications, indicating structured internal governance. Further information is available at alacris.de.

View profile
A

Akron Biotech

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors, human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy